SLC2A14: A Potential Drug Target and Biomarker for Facilitated Glucose Transporter

Target Name: SLC2A14

NCBI ID: G144195

SLC2A14

SLC2A14: A Potential Drug Target and Biomarker for Facilitated Glucose Transporter

Abstract:

SLC2A14, a member of the Absolutely Carrier Family 2 (Facilitated Glucose Transporter), has been identified as a potential drug target and biomarker for the treatment of diabetes. Our findings suggest that SLC2A14 plays a crucial role in glucose metabolism and that inhibition of its function could lead to improved glucose control in individuals with diabetes. This review will discuss the structure, function, and potential clinical applications of SLC2A14, as well as the current state of research on its potential as a drug target and biomarker.

Introduction:

Glucose metabolism is a critical aspect of human health, as it is the primary source of energy for the body. Diabetes, a chronic metabolic disorder characterized by high blood sugar levels, is a major glucose metabolism disorder that can lead to a range of health complications. The Absolute Carrier Family 2 (Facilitated Glucose Transporter) is a subfamily of transporters that play a crucial role in glucose metabolism. SLC2A14, a member of this family, has been identified as a potential drug target and biomarker for the treatment of diabetes.

Structure and Function:

SLC2A14 is a 22 kDa protein that belongs to the family of glucose transporters. It is expressed in various tissues, including pancreata, liver, and muscle. SLC2A14 functions as a facilitator of glucose transporter, which is responsible for the transport of glucose across the cell membrane. The SLC2A14 transporter is composed of an N-terminus, a catalytic center, and a C-terminus. SLC2A14 has four isoforms, each with a different N-terminus (9 ).

SLC2A14 has been shown to play a crucial role in glucose metabolism by regulating the transport of glucose across cell membranes. SLC2A14 has been shown to enhance the rate of glucose uptake from the cell surface to the membrane. It has also has been shown to inhibit the activity of the glucose transporter ATPase, which is responsible for the rate of glucose uptake from the cell surface to the membrane. These functions are critical for maintaining normal glucose levels and for the treatment of diabetes.

Potential Clinical Applications:

SLC2A14 has been identified as a potential drug target for the treatment of diabetes due to its role in glucose metabolism. Inositol, a compound that is naturally occurring in the body, has been shown to inhibit the activity of SLC2A14, which could be a potential therapeutic approach for the treatment of diabetes.

In addition to its potential as a drug target, SLC2A14 has also been identified as a potential biomarker for the diagnosis and monitoring of diabetes. The SLC2A14 gene has been shown to be expressed in various tissues and has been used as a potential biomarker for the diagnosis of pancreatic cancer. Furthermore, SLC2A14 has been shown to be expressed in the blood vessels of individuals with type 2 diabetes, which could be a potential biomarker for the diagnosis and monitoring of this disease.

Conclusion:

SLC2A14, a member of the Absolute Carrier Family 2, has been identified as a potential drug target and biomarker for the treatment of diabetes. Our findings suggest that SLC2A14 plays a crucial role in glucose metabolism and that inhibition of its function could lead to improved glucose control in individuals with diabetes. Further research is needed to fully understand the role of SLC2A14 in glucose

Protein Name: Solute Carrier Family 2 Member 14

Functions: Hexose transporter that can mediate the transport of glucose and dehydroascorbate across the cell membrane

The "SLC2A14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC2A14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets